219 related articles for article (PubMed ID: 11854391)
21. Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01).
Kawahara M; Tada H; Tokoro A; Teramukai S; Origasa H; Kubota K; Shinkai T; Fukushima M; Furuse K
BMC Cancer; 2011 Aug; 11():356. PubMed ID: 21849041
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
23. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
Wozniak AJ; Crowley JJ; Balcerzak SP; Weiss GR; Spiridonidis CH; Baker LH; Albain KS; Kelly K; Taylor SA; Gandara DR; Livingston RB
J Clin Oncol; 1998 Jul; 16(7):2459-65. PubMed ID: 9667264
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
Fiteni F; Anota A; Bonnetain F; Oster JP; Pichon E; Wislez M; Dauba J; Debieuvre D; Souquet PJ; Bigay-Game L; Molinier O; Dansin E; Poudenx M; Milleron B; Morin F; Zalcman G; Quoix E; Westeel V
Eur Respir J; 2016 Sep; 48(3):861-72. PubMed ID: 27338193
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
Paccagnella A; Favaretto A; Oniga F; Barbieri F; Ceresoli G; Torri W; Villa E; Verusio C; Cetto GL; Santo A; De Pangher V; Artioli F; Cacciani GC; Parodi G; Soresi F; Ghi MG; Morabito A; Biason R; Giusto M; Mosconi P; Chiarion Sileni V;
Lung Cancer; 2004 Jan; 43(1):83-91. PubMed ID: 14698542
[TBL] [Abstract][Full Text] [Related]
27. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.
Berthelot JM; Will BP; Evans WK; Coyle D; Earle CC; Bordeleau L
J Natl Cancer Inst; 2000 Aug; 92(16):1321-9. PubMed ID: 10944554
[TBL] [Abstract][Full Text] [Related]
28. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
29. Overview of economic analysis of Le Chevalier Vinorelbine Study.
Hillner BE; Smith TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):14-6; discussion 17. PubMed ID: 9556778
[TBL] [Abstract][Full Text] [Related]
30. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
Ng R; Hasan B; Mittmann N; Florescu M; Shepherd FA; Ding K; Butts CA; Cormier Y; Darling G; Goss GD; Inculet R; Seymour L; Winton TL; Evans WK; Leighl NB; ; ;
J Clin Oncol; 2007 Jun; 25(16):2256-61. PubMed ID: 17538170
[TBL] [Abstract][Full Text] [Related]
31. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
Evans WK; Le Chevalier T
Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients.
Schmittel A; Siehl JM; Schulze M; Schulze K; Thiel E; Keilholz U
Anticancer Res; 2005; 25(2B):1333-6. PubMed ID: 15865087
[TBL] [Abstract][Full Text] [Related]
33. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
Palmer AJ; Brandt A
Monaldi Arch Chest Dis; 1996 Aug; 51(4):279-88. PubMed ID: 8909011
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
Earle CC; Evans WK
Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
[TBL] [Abstract][Full Text] [Related]
36. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
Rosell R; Scagliotti G; Danenberg KD; Lord RV; Bepler G; Novello S; Cooc J; Crinò L; Sánchez JJ; Taron M; Boni C; De Marinis F; Tonato M; Marangolo M; Gozzelino F; Di Costanzo F; Rinaldi M; Salonga D; Stephens C
Oncogene; 2003 Jun; 22(23):3548-53. PubMed ID: 12789263
[TBL] [Abstract][Full Text] [Related]
37. [Advanced non-small cell lung cancer responded to both vinorelbine and carboplatin over long-term outpatient treatment].
Chohnabayashi N; Uchiyama N; Nishimura N; Nasu H
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1395-8. PubMed ID: 15446564
[TBL] [Abstract][Full Text] [Related]
38. Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.
Lilenbaum RC; Chen CS; Chidiac T; Schwarzenberger PO; Thant M; Versola M; Lane SR
Ann Oncol; 2005 Jan; 16(1):97-101. PubMed ID: 15598945
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Santana-Davila R; Szabo A; Arce-Lara C; Williams CD; Kelley MJ; Whittle J
J Thorac Oncol; 2014 May; 9(5):702-9. PubMed ID: 24662458
[TBL] [Abstract][Full Text] [Related]
40. Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test.
Kolek V; Grygarkova I; Hajduch M; Klein J; Cwiertka K; Neoral C; Langova K; Mihal V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Dec; 152(2):259-66. PubMed ID: 19219217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]